-
Atypical neural processing in 22q11.2 Deletion Syndrome and schizophrenia: Towards neuromarkers of disease progression and risk
Prof. Sophie MolholmDone
-
Phase-amplitude coupling in EEG as a Parkinsonian biomarker
Prof. Thomas R. KnöscheDone
-
Towards personalised neuromodulation in mental health: A non-invasive avenue of network research into dynamic brain circuits and their dysfunction
Prof. Marcus KaiserDone
-
Do I want to know? Artificial intelligence as a predictive tool in the diagnosis and treatment of cognitive impairment. Development of EEG-based functional network analyses
Prof. Ira Haraldsen, MDDone
-
Schizophrenia: A temporal disorder?
Dr. Annemarie WolffDone
-
Principles and challenges of fMRI-based ‘brain reading’
Prof. John-Dylan HaynesDone
-
High-fidelity continuous monitoring of physiology anywhere with RDS
Louis Mayaud, PhDDone
-
The Berger’s discovery revisited: How and why the brain’s dominant rhythm relates to cognition
Tzvetan Popov, PhDDone
-
Real brains in virtual worlds
Prof. Klaus GramannDone
-
Two clinical applications of hdEEG: Kinesthetic illusion and consciousness in sleep
Jan Hubený, Ing.Done
Martijn is Research director at the Brainclinics Foundation and associate professor at Maastricht University, Faculty of
Psychology & Neuroscience. His main interest is Stratified Psychiatry and Precision Psychiatry for Depression and ADHD, and brain
stimulation techniques such as rTMS.
Given relatively modest remission rates for antidepressant treatments available, there is a need for approaches that
help tailor existing treatments to the individual in order to improve remission rates. In addition, such techniques should be clinically
actionable and well validated in blinded out-of-sample validations. Here we introduce the concept of Stratified Psychiatry, that is
better suited for implementation in clinical practice, and demonstrate that Brainmarker-I, an EEG biomarker, can successfully help
stratify patients between 1-Hz right and 10-Hz left rTMS, as well as for ECT and various other antidepressant treatments, as a
clinically actionable stratification marker. Furthermore, a novel update of NCG-TMS called Heart-Brain Coupling is introduced that
provides real time evidence of frontal-vagal activation, simply measured using an iPhone app. This technique not only helps identify
the right target for frontal-vagal activation, but also provides frontal excitability thresholds (which are known to differ substantially
from motor-thresholds).